Log in

NASDAQ:CRTXCortexyme Stock Price, Forecast & News

+2.58 (+5.93 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $46.09
50-Day Range
MA: $46.48
52-Week Range
Now: $46.09
Volume409,156 shs
Average Volume154,375 shs
Market Capitalization$1.36 billion
P/E RatioN/A
Dividend YieldN/A
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
Current SymbolNASDAQ:CRTX



Sales & Book Value

Annual SalesN/A
Book Value$7.41 per share


Net Income$-36,980,000.00


Market Cap$1.36 billion
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

How has Cortexyme's stock been impacted by COVID-19 (Coronavirus)?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRTX stock has increased by 24.5% and is now trading at $46.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cortexyme?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cortexyme.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Cortexyme.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) issued its quarterly earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.16. View Cortexyme's earnings history.

What price target have analysts set for CRTX?

3 equities research analysts have issued 1 year price targets for Cortexyme's stock. Their forecasts range from $14.00 to $70.00. On average, they anticipate Cortexyme's share price to reach $41.25 in the next year. This suggests that the stock has a possible downside of 10.5%. View analysts' price targets for Cortexyme.

Has Cortexyme been receiving favorable news coverage?

News coverage about CRTX stock has trended very negative on Saturday, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cortexyme earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutCortexyme.

Are investors shorting Cortexyme?

Cortexyme saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,060,000 shares, an increase of 21.2% from the April 30th total of 1,700,000 shares. Based on an average daily volume of 129,300 shares, the days-to-cover ratio is currently 15.9 days. Currently, 17.4% of the company's stock are short sold. View Cortexyme's Current Options Chain.

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Honeywell International (HON), AT&T (T), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Thermo Fisher Scientific (TMO) and Home Depot (HD).

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
  • Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
  • Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
  • Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 52)

When did Cortexyme IPO?

(CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (8.64%), Capital International Investors (3.35%), Capital World Investors (2.53%), BlackRock Inc. (2.22%), State Street Corp (0.66%) and Geode Capital Management LLC (0.46%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc. View institutional ownership trends for Cortexyme.

Which major investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Invesco Ltd., Alps Advisors Inc., Virtus ETF Advisers LLC, Alliancebernstein L.P., UBS Group AG, Legal & General Group Plc, and American International Group Inc.. View insider buying and selling activity for Cortexyme.

Which major investors are buying Cortexyme stock?

CRTX stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Pacific Heights Asset Management LLC, Capital Research Global Investors, BlackRock Inc., Capital International Investors, Geode Capital Management LLC, Ikarian Capital LLC, and State Street Corp. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc. View insider buying and selling activity for Cortexyme.

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $46.09.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $1.36 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe.

What is Cortexyme's official website?

The official website for Cortexyme is www.cortexyme.com.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.